VRTX — VERTEX PHARMACEUTICALS INC / MA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 875320 ·
Last close
$506.74
Market Cap
$128.44B
52W High
$560.25
52W Low
$400.74
ADV30
998,019
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,333,900,000 | 2,844,700,000 | 1,268,700,000 | 1,099,800,000 | 27,423,300,000 | 6,143,500,000 | 7,175,400,000 |
| Mar 2026 | 2,986,900,000 | 2,594,100,000 | 1,138,800,000 | 1,031,400,000 | 26,484,400,000 | 5,492,900,000 | 7,122,500,000 |
| Dec 2025 | 3,190,000,000 | 2,724,000,000 | 1,130,300,000 | 1,191,100,000 | 25,643,000,000 | 5,084,800,000 | 6,977,200,000 |
| Sep 2025 | 3,076,400,000 | 2,661,600,000 | 1,238,800,000 | 1,082,900,000 | 24,862,300,000 | 4,939,600,000 | 7,543,500,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$4,292,900,000
Investing CF
$-882,800,000
Financing CF
$-2,197,200,000
CapEx
$-496,800,000
Dividends Paid
—
Buybacks
$-2,332,200,000
EPS Diluted TTM
$17.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$15,691,200,000
Inventory
$1,765,100,000
Receivables
$2,134,300,000
ST Investments
$1,708,900,000
EBIT TTM
$5,043,900,000
Pretax Income TTM
$5,274,500,000
Interest Exp TTM
$13,300,000
Analysts
25
Yahoo Snapshot (yfinance, live)
Total Revenue
$12,587,200,512
EBITDA
$5,100,499,968
Free Cash Flow
$2,627,887,616
Enterprise Value
$124,769,099,776
Total Cash
$7,852,400,128
Total Debt
$1,977,600,000
Shares Out
253,460,924
Trailing EPS
$17.16
Book Value
$79.92
ROE
23.5%
ROA
11.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 12,001,300,000 | 4,554,400,000 | 3,953,200,000 | 25,643,000,000 | 6,977,200,000 | 18,665,800,000 | 3,631,400,000 |
| Dec 2024 | 11,020,100,000 | -233,400,000 | -535,600,000 | 22,533,200,000 | 6,123,600,000 | 16,409,600,000 | -492,600,000 |
| Dec 2023 | 9,869,200,000 | 3,780,400,000 | 3,619,600,000 | 22,730,200,000 | 5,149,800,000 | 17,580,400,000 | 3,537,300,000 |
| Dec 2022 | 8,930,700,000 | 4,249,900,000 | 3,322,000,000 | 18,150,900,000 | 4,238,200,000 | 13,912,700,000 | 4,129,900,000 |
TTM Snapshot
Revenues TTM
$10,359,900,000
NetIncome TTM
$3,657,500,000
OpCashFlow TTM
$0
Assets (Latest)
$25,643,000,000
Forward EPS
$20.13
Max Pain — expiry 2026-10-16
max pain strike: $515.00 · spot: $506.74 · call oi: 3,569 · put oi: 3,142
Expected Move to 2026-10-16:
±$19.04
(3.76%) —
implied range
$487.70 –
$525.78
· ATM straddle on $505.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BMY | BRISTOL MYERS SQUIBB CO | $125.55B | $61.46 | — |
| NVO | NOVO NORDISK A S | $125.07B | $37.40 | — |
| PFE | PFIZER INC | $160.27B | $28.12 | — |
| ABT | ABBOTT LABORATORIES | $167.31B | $96.69 | — |
| SNY | Sanofi | $97.45B | $40.67 | — |
News headlines (Yahoo Finance, 1h cache)
Vertex Pharmaceuticals And 2 Other Top Gene Therapy Stocks
2026-10-01 22:07 · Yahoo
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-10-01 21:00 · Yahoo
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
2026-10-01 19:17 · Yahoo
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right.
2026-09-29 09:30 · Yahoo
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
2026-09-29 00:37 · Yahoo
2 Healthcare Stocks That Just Delivered Great News for Investors
2026-09-26 20:21 · Yahoo
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
2026-09-24 20:50 · Yahoo
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
2026-09-24 14:27 · Yahoo
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-24 13:02 · Yahoo
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
2026-09-24 03:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.